US EditionGRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
GRI Bio meets interim clinical trial enrollment goal for IPF therapy
GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a therapy targeting natural killer T-cells (NKT cells) to treat idiopathic pulmonary fibrosis (IPF) — and expects to report initial results later this quarter, per a company press release. With 24 of an expected 36 participants enrolled, the company said it’s on track to complete a planned analysis of the therapy’s safety and efficacy after six week…
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio (NASDAQ: GRI) has announced significant progress in its Phase 2a clinical trial of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF). The study has completed enrollment for the 6-week interim analysis with 24 out of 36 planned patients now enrolled. The randomized, double-blind study administers GRI-0621 4.5mg or placebo orally once daily for 12 weeks. Previously reported 2-week safety results from the first 12 patients showed the drug to…
Santa Cruz de Tenerife. A team from the Research Unit of the University Hospital Nuestra Señora de Candelaria and the Primary Care Management of Tenerif, led an international study in which an association has been discovered between rare genetic variants in pulmonary fibrosis and a lower survival rate of patients. This research represents a significant advance in understanding the role of genetic factors in the progression of idiopathic pulmonar…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage